Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with
PD-1 antibody for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond
up-to-seven criteria